Enanta Pharmaceuticals Director Stephen Jr. Buckley Acquires 1,000 Shares (ENTA)
Enanta Pharmaceuticals (NASDAQ:ENTA) Director Stephen Jr. Buckley acquired 1,000 shares of the company’s stock on the open market in a transaction dated Thursday, August 14th. The shares were purchased at an average price of $38.95 per share, with a total value of $38,950.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $38,950. The acquisition was disclosed in a document filed with the SEC, which is available at this link.
Enanta Pharmaceuticals (NASDAQ:ENTA) traded up 1.53% on Friday, hitting $39.79. The stock had a trading volume of 269,263 shares. Enanta Pharmaceuticals has a 52 week low of $18.21 and a 52 week high of $46.443. The stock has a 50-day moving average of $39.61 and a 200-day moving average of $38.36. The company has a market cap of $739.4 million and a P/E ratio of 21.10.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, August 11th. The company reported $2.61 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.67 by $0.94. The company had revenue of $42.10 million for the quarter, compared to the consensus estimate of $40.83 million. The company’s quarterly revenue was up 2531.3% on a year-over-year basis. On average, analysts predict that Enanta Pharmaceuticals will post $1.35 earnings per share for the current fiscal year.
ENTA has been the subject of a number of recent research reports. Analysts at Credit Suisse raised their price target on shares of Enanta Pharmaceuticals from $43.00 to $44.00 in a research note on Friday. They now have an “outperform” rating on the stock. Separately, analysts at FBR Capital Markets initiated coverage on shares of Enanta Pharmaceuticals in a research note on Thursday. They set an “outperform” rating and a $52.00 price target on the stock. Finally, analysts at Zacks upgraded shares of Enanta Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday. They now have a $47.10 price target on the stock. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $45.82.
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.
Receive News & Ratings for Enanta Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.